LinkedIn
WebsiteIntroduction
ClearPoint Neuro Inc. (NASDAQ: CLPT) is a device, cell, and gene therapy–enabling company headquartered in Solana Beach, California. Founded in 1998, it offers navigation solutions for the brain and spine, supporting over 90 neurosurgery centers worldwide. Its platform has guided more than 7,000 procedures and collaborates with over 60 partners in biologics and drug delivery.
Corporate Structure and Operations
As of September 2025, ClearPoint Neuro employs between 51 and 200 staff across three primary locations:
- 120 S Sierra Ave, Suite 1, Solana Beach, California, US
- 5 Musick, Irvine, California, US
- Zurich House (Office 7), Hulley Road, Macclesfield, Cheshire, GB
Key leadership includes Tim Richards (Global COO & CMO), Chris Yelley (Vice President, Operations), and Mazin Sabra (Chief Operating Officer). The company provides both established clinical devices and preclinical development services for controlled drug delivery, engaging research centers across North America, Europe, Asia, and South America.
Neuro device by Maxim Potkin ❄
Recent Developments and News
- On September 24, 2025, CLPT shares closed at $17.35, reflecting a 42.68% increase on a volume of 1,062,390, following announcements of new trial collaborations.
- On May 22–23, 2025, ClearPoint Neuro presented its CE-marked laser interstitial thermal therapy portfolio at the euLITT Workshop in Naples, Italy.
- During the ASGCT Conference in May 2025, the company hosted a poster session and had an exhibit at booth 1648 to feature its image-guided delivery systems.
Financial and Strategic Analysis
The 42.68% increase in share price on September 24 is indicative of investor interest in ClearPoint Neuro’s positioning within central nervous system (CNS) drug delivery trials. Revenue streams are derived from the sales of navigation platforms and consumables as well as contracted preclinical services. Strategic partnerships with over 60 biologics developers are noted as contributing to the company’s pipeline visibility. Its proprietary real-time MRI guidance provides procedural flexibility and may support reimbursement pathways.
Market Position and Industry Context
The global neuro device market is expanding as cell and gene therapies for neurological disorders advance. ClearPoint Neuro’s specialization in MRI- and iCT-guided delivery distinguishes it from other surgical navigation providers. Supported by CE marking and a network of over 90 neurosurgery centers, the company is positioned to address the increasing demand for precision CNS delivery solutions.
tl;dr
- On September 24, 2025, CLPT shares increased by 42.68% to $17.35 on Nasdaq.
- In May 2025, the company presented its CE-marked neuro delivery systems at euLITT (May 22–23, Naples) and ASGCT.
- Revenue comprises device sales and preclinical services, supported by over 60 biologics partnerships.
- Utilizing MRI-guided precision and collaborating with over 90 global centers, ClearPoint Neuro supports ongoing CNS gene and cell therapy trials.
- Upcoming catalysts include trial enrollments and regulatory approvals for new therapeutic indications.
